Coronary anatomy: Difference between revisions

 
(9 intermediate revisions by 2 users not shown)
Line 41: Line 41:
Patients with older age, diabetes mellitus, chronic renal insufficiency, multivessel disease, low ejection fraction have a higher risk of complications.
Patients with older age, diabetes mellitus, chronic renal insufficiency, multivessel disease, low ejection fraction have a higher risk of complications.


=Time-out procedure=
In surgery, the use of a pre-operative checklist has improved the outcome. Implementation of a 19-item surgical safety checklist improved team communication and reduced rates of death and complications in patients undergoing noncardiac surgery<cite>Haynes</cite>. Implementation of a comprehensive preoperative checklist targeting the entire surgical pathway (including items such as medication, marking of operative side and the use of postoperatieve instructions) was associated with a reduction in surgical complications and mortality in hospitals with a high standard of care<cite>deVries</cite>.
Although the goal of most procedures in interventional cardiology is to access the heart and its associated vasculature (making wrong site procedures less of a concern), a preprocedure checklist is also recommended in the catheterization laboratory<cite>Naidu</cite>. Information obtained preprocedural should include procedural indication, patients history, informed consent, a review of medication (in particular antiplatelet therapies and metformin) and a risk of bleeding assessment. Renal function should be less than 90 days old. If the patient is using VKA an INR is obtained < 24 preprocedural.  Images of prior catheterizations are obtained and procedural reports of any coronary or peripheral bypass surgery reviewed. The history should be reviewed for previous heparin-induced thrombocytopenia (HIT). Allergies should be checked, especially contrast allergies or allergies to medication used periprocedural (p.e. heparin). Each laboratory has a protocol for preventing contrast allergic reaction (using p.e. Prednison and an antihistaminic).
Before procedure a time-out procedure is performed by all team members before vascular access is obtained. Patient identification should be checked and confirmed and agreement on the right procedure obtained. Figure 1 shows a sample of a time-out checklist.
Figure 1
<br/>
Sample ‘‘Time Out’’ Preprocedure Checklist
The physician taking ultimate responsibility for the procedure should lead the Time Out and ensure each of the following items is announced:
#Patient’s name and medical record number
#Procedure to be performed (e.g., left heart catheterization, coronary angiography, right heart catheterization)
#Route to be used (e.g., right femoral artery)
#Confirm that the equipment needed is available or alternatives are available including intended stent type for PCI or cath-possible patients
#Patient’s allergies and premedication if appropriate (e.g., heparin-induced thrombocytopenia, contrast allergy)
#Special laboratory or medical conditions (e.g., elevated INR, chronic kidney disease)
=Vascular Access Site=
=Vascular Access Site=
Before Judkins developed the percutaneous transfemoral approach in the late sixties, brachial arteriotomy was performed to introduce the catheter. This is seldomly used nowadays. In the majority of cases arterial catheters are introduced via the femoral artery or radial artery using the Seldinger technique.
Before Judkins developed the percutaneous transfemoral approach in the late sixties, brachial arteriotomy was performed to introduce the catheter. This is seldomly used nowadays. In the majority of cases arterial catheters are introduced via the femoral artery or radial artery using the Seldinger technique.
Line 81: Line 99:
*LAO 20 cranial 25                      Crux, RDP and RPL
*LAO 20 cranial 25                      Crux, RDP and RPL


[[File:RecommendedRadiographicProjections.png]]
[[File:RecommendedRadiographicProjections_03072014.png]]
LAO 45
LAO 45


Line 113: Line 131:


For collateral connections, it is necessary to make longer angiographic projections. In a RCA obstruction, intercoronary collaterals can form between the septal branches of the LAD and the RDP through the interventricular septum. Collaterals connecting distal portions of two arteries are frequently observed, p.e. connections between the distal RCx and RCA in the interventricular groove and between diagonal branches of the LAD. A collateral between the conus branch of the RCA to the proximal LAD is called a ring of Vieussens. Atrial branches from the RCA or the Kugel’s artery (mostly an small artery arising from proximal RCA anastomosing with branches of sinus node artery) can form connections between the proximal and distal RCA.
For collateral connections, it is necessary to make longer angiographic projections. In a RCA obstruction, intercoronary collaterals can form between the septal branches of the LAD and the RDP through the interventricular septum. Collaterals connecting distal portions of two arteries are frequently observed, p.e. connections between the distal RCx and RCA in the interventricular groove and between diagonal branches of the LAD. A collateral between the conus branch of the RCA to the proximal LAD is called a ring of Vieussens. Atrial branches from the RCA or the Kugel’s artery (mostly an small artery arising from proximal RCA anastomosing with branches of sinus node artery) can form connections between the proximal and distal RCA.
=Time-out procedure=
In surgery, the use of a pre-operative checklist has improved the outcome. Implementation of a 19-item surgical safety checklist improved team communication and reduced rates of death and complications in patients undergoing noncardiac surgery<cite>Haynes</cite>. Implementation of a comprehensive preoperative checklist targeting the entire surgical pathway (including items such as medication, marking of operative side and the use of postoperatieve instructions) was associated with a reduction in surgical complications and mortality in hospitals with a high standard of care<cite>deVries</cite>.
Although the goal of most procedures in interventional cardiology is to access the heart and its associated vasculature (making wrong site procedures less of a concern), a preprocedure checklist is also recommended in the catheterization laboratory<cite>Naidu</cite>. Information obtained preprocedural should include procedural indication, patients history, informed consent, a review of medication (in particular antiplatelet therapies and metformin) and a risk of bleeding assessment. Renal function should be less than 90 days old. If the patient is using VKA an INR is obtained < 24 preprocedural.  Images of prior catheterizations are obtained and procedural reports of any coronary or peripheral bypass surgery reviewed. The history should be reviewed for previous heparin-induced thrombocytopenia (HIT). Allergies should be checked, especially contrast allergies or allergies to medication used periprocedural (p.e. heparin). Each laboratory has a protocol for preventing contrast allergic reaction (using p.e. Prednison and an antihistaminic).
Before procedure a time-out procedure is performed by all team members before vascular access is obtained. Patient identification should be checked and confirmed and agreement on the right procedure obtained. Figure 1 shows a sample of a time-out checklist.
Figure 1
<br/>
Sample ‘‘Time Out’’ Preprocedure Checklist
The physician taking ultimate responsibility for the procedure should lead the Time Out and ensure each of the following items is announced:
#Patient’s name and medical record number
#Procedure to be performed (e.g., left heart catheterization, coronary angiography, right heart catheterization)
#Route to be used (e.g., right femoral artery)
#Confirm that the equipment needed is available or alternatives are available including intended stent type for PCI or cath-possible patients
#Patient’s allergies and premedication if appropriate (e.g., heparin-induced thrombocytopenia, contrast allergy)
#Special laboratory or medical conditions (e.g., elevated INR, chronic kidney disease)


=Left ventriculography=
=Left ventriculography=
Line 237: Line 236:
<br/>
<br/>
In one meta-analyses including 7 randomized trials with STEMI patients with cardiogenic shock, IABP showed neither a 30-day survival benefit nor improved left ventricular ejection fraction, and was associatied with more complications (higher stroke, higher bleeding rates). Another meta-analysis included 9 cohorts with STEMI patients with cardiogenic shock, and showed that IABP was associated with an 18% decrease in 30 day mortality, but with significantly higher revascularization rates and higher mortality in the PCI group<cite>EurHeart2</cite>.  In the randomized controlled trial Shock II, publiced in the NEJM in 2012, the use of IABP did not significantly reduce the 30-day mortality in patients with cardiogenic shock complicating acute myocardial infarction for whom an early revascularization strategy was planned<cite>Thiele</cite>.
In one meta-analyses including 7 randomized trials with STEMI patients with cardiogenic shock, IABP showed neither a 30-day survival benefit nor improved left ventricular ejection fraction, and was associatied with more complications (higher stroke, higher bleeding rates). Another meta-analysis included 9 cohorts with STEMI patients with cardiogenic shock, and showed that IABP was associated with an 18% decrease in 30 day mortality, but with significantly higher revascularization rates and higher mortality in the PCI group<cite>EurHeart2</cite>.  In the randomized controlled trial Shock II, publiced in the NEJM in 2012, the use of IABP did not significantly reduce the 30-day mortality in patients with cardiogenic shock complicating acute myocardial infarction for whom an early revascularization strategy was planned<cite>Thiele</cite>.
= Other circulatory assist devices: Impella =
The Impella device is an axial flow pump on a catheter.  The system has an electromagnetic motor directy coupled to a helical impeller located near the tip of a catheter. When the “snorkel” at the tip of the catheter is placed across the aortic valve and into the left ventricular chamber, the motor rotates the impeller at 50.000 rpm, drawing ventricular blood into the distal end of the catheter and discharging it non-pulsatile into the ascending aorta. The device can be placed via the femoral artery in a 9 Fr sheath. There are 2 versions: a 2.5 and a 5L (33.000 rpm), with maximal outputs of respectively 2.5 and 5.0L/min. Before placement an echocardiography should rule out LV thrombus<cite>Engstrom</cite>.
Possible indications for Impella placement are high risk PCI and cardiogenic shock.
In 2012, the PROTECT II trial randomized 452 patients with 3-vessel of left main coronary artery disease and severely depressed left ventricular function to an Impella (2.5L) or an IABP. The Impella provided superior hemodynamic support, but with no difference in the 30 days endpoint of major adverse events<cite>Cardiol</cite>.
In 2008, a multicenter registry showed the Impella 2.5 to be safe and potentially useful in hemodynamic support in high-risk PCI (multivessel, left main, last remaining vessel, low LV function) with rates of myocardial infarction, stroke, bleeding and vascular complications at 30 days of 6.2%<cite>Oneill</cite>.
[[File:Impella.jpg|thumb|400px|Example of a 2.5L Impella system<cite>McCulloch</cite>]]
<br/>


= References =
= References =
Line 264: Line 276:
#EurHeart2 pmid=19168529
#EurHeart2 pmid=19168529
#Thiele pmid=22920912
#Thiele pmid=22920912
#Engstrom pmid=21118589
#Cardiol pmid=20082934
#Oneill pmid=22935569
#McCulloch  pmid=21285459
</biblio>
</biblio>